CVKD

Insider trade Sale by Pham Quang X (CEO and Chairman)

3d ago

Insider trade Sale by Pham Quang X (CEO and Chairman)

6d ago

News Cadrenal Therapeutics reports Q1 results

26d ago

SEC filing CVKD Reports $2.5M Net Loss, $2.3M Cash, Advances Phase 3 CAD-1005 HIT Trial, FDA Guidance Received, $2.5M Financing Closed

26d ago

News Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

155d ago

SEC filing CVKD Raises $2.2M via Direct Offering, Issues 207K Shares, 414K Warrants at $10.85/Share

168d ago